Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | DRD5 | P21918 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438257 | 1.00 | MAPT (0.49) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9132456 | 0.85 | MAPT (0.47) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9133313 | 0.85 | CYP2C19 (0.45) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9130617 | 0.84 | PDE4A (0.37) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9132031 | 0.84 | MAPT (0.44) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9535601 | 0.84 | MAPT (0.50) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9132455 | 0.84 | MAPT (0.48) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9134909 | 0.83 | MAPT (0.43) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9131645 | 0.83 | MAPT (0.43) | MAPTHPGDCYP2C19MEN1CYP1A2 | |
| SCHEMBL9726870 | 0.83 | CYP2C19 (0.47) | MAPTHPGDCYP2C19MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4810708-A | ANTIALLERGY, IMMUNOSUPPRESSIVE | SCHERING CORPORATION (US) | 1989-03-07 | — | — | US | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | disclosed |
| US-5439916-A | Antiallergens,-inflammatory and -ulcer agents; hypotensive agents; immunosuppressants; skin disorders | SCHERING CORPORATION (US) | 1995-08-08 | — | — | US | disclosed |
| US-5126352-A | Antiallergy, antiinflammatory, antiulcer, hypotensive, antibody inhibitors | SCHERING CORPORATION (US) | 1992-06-30 | — | — | US | disclosed |
| US-5116840-A | Antiulcer, antiinflammatory, hypotensive, immunosuppressants | SCHERING CORPORATION (US) | 1992-05-26 | — | — | US | disclosed |
| US-4988705-A | Antiallergens and -inflammatory agents; hypotensive agents immunological suppression; hyperproliferative skin disorders such as psoriasis | SCHERING CORPORATION (US) | 1991-01-29 | — | — | US | disclosed |
| US-4810708-A | ANTIALLERGY, IMMUNOSUPPRESSIVE | SCHERING CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | MAPT 2546/4885HPGD 285/4885CYP2C19 386/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | MAPT 2546/4885HPGD 285/4885CYP2C19 386/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | MAPT 4859/4885HPGD 642/4885CYP2C19 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.